52 Editorial Board Members of Cancer Drug Resistance Recognized in the "World's Top 2% Scientists 2025" List

Stanford University and Elsevier jointly released the "World's Top 2% Scientists 2025" list on September 19, 2025. This prestigious ranking evaluates researchers' influence from two dimensions: Career-long Impact, which reflects lifetime scientific contributions, and Single-year Impact, which highlights academic achievements within the past year.

We are delighted to announce that 52 Editorial Board members of Cancer Drug Resistance (CDR) have been included in this year's list:

• 29 members were featured in both the Career-long and Single-year Impact categories.
• 4 members were listed in the Career-long Impact category.
• 19 members were recognized in the Single-year Impact category, underscoring their outstanding contributions in the past year.

(Note: Names are listed in no particular order. For any corrections or updates regarding the statistics, please contact the CDR Editorial Office.)

Editorial Board Members Recognized in Both Career-long and Single-year Impact Rankings

Editorial Board Members Recognized in the Career-long Impact Ranking

Editorial Board Members Recognized in the Single-year Impact Ranking

The World's Top 2% Scientists 2025 ranking is based on comprehensive data from the Scopus database, using six key indicators: total citations (with and without self-citations), the Hirsch H-index, the Schreiber Hm-index (adjusted for co-authorship), and weighted authorship roles (sole, first, or lead author). Out of nearly 7 million researchers worldwide, only the top 2% across 22 scientific fields and 174 subfields are included, reflecting the rigor and prestige of this recognition.

The inclusion of such a large number of CDR Editorial Board members in this year's ranking not only affirms their exceptional academic influence but also highlights CDR's growing reputation as a leading platform for publishing cutting-edge research in cancer drug resistance.

We warmly congratulate all recognized Editorial Board members on this remarkable achievement and look forward to their continued contributions and groundbreaking advances in global science and medicine.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance